Inclacumab - Global Blood Therapeutics/Roche

Drug Profile

Inclacumab - Global Blood Therapeutics/Roche

Alternative Names: DSM ACC2641; LC1004-002; R 1512; RG1512; RO 4905417

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab; Roche
  • Developer Roche
  • Class Anti-inflammatories; Anti-ischaemics; Monoclonal antibodies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Myocardial infarction; Peripheral vascular disorders

Most Recent Events

  • 23 Aug 2018 Inclacumab licensed to Global Blood Therapeutics worldwide
  • 23 Aug 2018 Global Blood Therapeutics announces intention to submit Investigational New Drug application to the US FDA for Sickle cell anaemia in 2021
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top